BIOSYENT INC (RX.CA) Fundamental Analysis & Valuation
TSX-V:RX • CA0906901081
Current stock price
14.5 CAD
-0.25 (-1.69%)
Last:
This RX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RX.CA Profitability Analysis
1.1 Basic Checks
- RX had positive earnings in the past year.
- In the past year RX had a positive cash flow from operations.
- RX had positive earnings in each of the past 5 years.
- Each year in the past 5 years RX had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 18.23%, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 21.73%, RX belongs to the top of the industry, outperforming 93.55% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 19.99%, RX belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for RX is significantly above the industry average of 9.14%.
- The 3 year average ROIC (18.14%) for RX is below the current ROIC(19.99%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.23% | ||
| ROE | 21.73% | ||
| ROIC | 19.99% |
ROA(3y)17.12%
ROA(5y)16.35%
ROE(3y)20.36%
ROE(5y)19.47%
ROIC(3y)18.14%
ROIC(5y)17.62%
1.3 Margins
- With an excellent Profit Margin value of 20.93%, RX belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
- RX's Profit Margin has improved in the last couple of years.
- RX has a Operating Margin of 26.28%. This is amongst the best in the industry. RX outperforms 87.10% of its industry peers.
- RX's Operating Margin has improved in the last couple of years.
- The Gross Margin of RX (76.57%) is better than 93.55% of its industry peers.
- In the last couple of years the Gross Margin of RX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.28% | ||
| PM (TTM) | 20.93% | ||
| GM | 76.57% |
OM growth 3Y1.52%
OM growth 5Y2.74%
PM growth 3Y2.31%
PM growth 5Y4.26%
GM growth 3Y-2.2%
GM growth 5Y-0.38%
2. RX.CA Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RX is creating value.
- RX has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for RX has been reduced compared to 5 years ago.
- RX has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 16.36 indicates that RX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of RX (16.36) is better than 100.00% of its industry peers.
- The Debt to FCF ratio of RX is 0.09, which is an excellent value as it means it would take RX, only 0.09 years of fcf income to pay off all of its debts.
- RX has a Debt to FCF ratio of 0.09. This is amongst the best in the industry. RX outperforms 100.00% of its industry peers.
- RX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.02, RX is doing good in the industry, outperforming 77.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.09 | ||
| Altman-Z | 16.36 |
ROIC/WACC2.3
WACC8.69%
2.3 Liquidity
- RX has a Current Ratio of 5.51. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 5.51, RX belongs to the top of the industry, outperforming 96.77% of the companies in the same industry.
- RX has a Quick Ratio of 4.63. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
- RX's Quick ratio of 4.63 is amongst the best of the industry. RX outperforms 96.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.51 | ||
| Quick Ratio | 4.63 |
3. RX.CA Growth Analysis
3.1 Past
- RX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.16%, which is quite impressive.
- RX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 21.99% yearly.
- Looking at the last year, RX shows a very strong growth in Revenue. The Revenue has grown by 22.90%.
- RX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.03% yearly.
EPS 1Y (TTM)27.16%
EPS 3Y21.63%
EPS 5Y21.99%
EPS Q2Q%25.71%
Revenue 1Y (TTM)22.9%
Revenue growth 3Y15.52%
Revenue growth 5Y14.03%
Sales Q2Q%9.95%
3.2 Future
- RX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.09% yearly.
- The Revenue is expected to grow by 24.23% on average over the next years. This is a very strong growth
EPS Next Y27.03%
EPS Next 2Y23.02%
EPS Next 3Y19.09%
EPS Next 5YN/A
Revenue Next Year57.34%
Revenue Next 2Y34.61%
Revenue Next 3Y24.23%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. RX.CA Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 18.59 indicates a rather expensive valuation of RX.
- Based on the Price/Earnings ratio, RX is valued a bit cheaper than the industry average as 77.42% of the companies are valued more expensively.
- RX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.91.
- With a Price/Forward Earnings ratio of 15.12, RX is valued correctly.
- RX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. RX is cheaper than 74.19% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 21.99. RX is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.59 | ||
| Fwd PE | 15.12 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, RX is valued a bit cheaper than 67.74% of the companies in the same industry.
- 67.74% of the companies in the same industry are more expensive than RX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.8 | ||
| EV/EBITDA | 11.2 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- RX has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as RX's earnings are expected to grow with 19.09% in the coming years.
PEG (NY)0.69
PEG (5Y)0.85
EPS Next 2Y23.02%
EPS Next 3Y19.09%
5. RX.CA Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 1.37%, RX has a reasonable but not impressive dividend return.
- RX's Dividend Yield is rather good when compared to the industry average which is at 0.27. RX pays more dividend than 93.55% of the companies in the same industry.
- RX's Dividend Yield is slightly below the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.37% |
5.2 History
- RX has been paying a dividend for over 5 years, so it has already some track record.
- RX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- RX pays out 24.99% of its income as dividend. This is a sustainable payout ratio.
DP24.99%
EPS Next 2Y23.02%
EPS Next 3Y19.09%
RX.CA Fundamentals: All Metrics, Ratios and Statistics
TSX-V:RX (4/28/2026, 7:00:00 PM)
14.5
-0.25 (-1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength40.16
Industry Growth47.76
Earnings (Last)03-19 2026-03-19
Earnings (Next)05-14 2026-05-14
Inst Owners3.68%
Inst Owner ChangeN/A
Ins Owners17.46%
Ins Owner ChangeN/A
Market Cap168.34M
Revenue(TTM)43.05M
Net Income(TTM)9.01M
Analysts82.86
Price Target16.83 (16.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.37% |
Yearly Dividend0.2
Dividend Growth(5Y)N/A
DP24.99%
Div Incr Years3
Div Non Decr Years3
Ex-Date02-27 2026-02-27 (0.055)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.22%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)8.05%
EPS NY rev (3m)8.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)52.78%
Revenue NY rev (3m)52.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.59 | ||
| Fwd PE | 15.12 | ||
| P/S | 3.91 | ||
| P/FCF | 18.8 | ||
| P/OCF | 18.69 | ||
| P/B | 4.06 | ||
| P/tB | 4.59 | ||
| EV/EBITDA | 11.2 |
EPS(TTM)0.78
EY5.38%
EPS(NY)0.96
Fwd EY6.61%
FCF(TTM)0.77
FCFY5.32%
OCF(TTM)0.78
OCFY5.35%
SpS3.71
BVpS3.57
TBVpS3.16
PEG (NY)0.69
PEG (5Y)0.85
Graham Number7.9171 (-45.4%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.23% | ||
| ROE | 21.73% | ||
| ROCE | 26.79% | ||
| ROIC | 19.99% | ||
| ROICexc | 62.2% | ||
| ROICexgc | 96.2% | ||
| OM | 26.28% | ||
| PM (TTM) | 20.93% | ||
| GM | 76.57% | ||
| FCFM | 20.8% |
ROA(3y)17.12%
ROA(5y)16.35%
ROE(3y)20.36%
ROE(5y)19.47%
ROIC(3y)18.14%
ROIC(5y)17.62%
ROICexc(3y)51.1%
ROICexc(5y)73.45%
ROICexgc(3y)68.78%
ROICexgc(5y)93.96%
ROCE(3y)24.31%
ROCE(5y)23.62%
ROICexgc growth 3Y-3.62%
ROICexgc growth 5Y-14.21%
ROICexc growth 3Y-10.31%
ROICexc growth 5Y-14.23%
OM growth 3Y1.52%
OM growth 5Y2.74%
PM growth 3Y2.31%
PM growth 5Y4.26%
GM growth 3Y-2.2%
GM growth 5Y-0.38%
F-Score7
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.09 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | 6.33% | ||
| Cap/Sales | 0.13% | ||
| Interest Coverage | 229.01 | ||
| Cash Conversion | 74.05% | ||
| Profit Quality | 99.37% | ||
| Current Ratio | 5.51 | ||
| Quick Ratio | 4.63 | ||
| Altman-Z | 16.36 |
F-Score7
WACC8.69%
ROIC/WACC2.3
Cap/Depr(3y)8.86%
Cap/Depr(5y)11.1%
Cap/Sales(3y)0.14%
Cap/Sales(5y)0.18%
Profit Quality(3y)98.43%
Profit Quality(5y)91.63%
High Growth Momentum
Growth
EPS 1Y (TTM)27.16%
EPS 3Y21.63%
EPS 5Y21.99%
EPS Q2Q%25.71%
EPS Next Y27.03%
EPS Next 2Y23.02%
EPS Next 3Y19.09%
EPS Next 5YN/A
Revenue 1Y (TTM)22.9%
Revenue growth 3Y15.52%
Revenue growth 5Y14.03%
Sales Q2Q%9.95%
Revenue Next Year57.34%
Revenue Next 2Y34.61%
Revenue Next 3Y24.23%
Revenue Next 5YN/A
EBIT growth 1Y24.81%
EBIT growth 3Y17.28%
EBIT growth 5Y17.16%
EBIT Next Year38.85%
EBIT Next 3Y20.9%
EBIT Next 5YN/A
FCF growth 1Y3.87%
FCF growth 3Y22.25%
FCF growth 5Y5.41%
OCF growth 1Y3.99%
OCF growth 3Y22.1%
OCF growth 5Y5.5%
BIOSYENT INC / RX.CA Fundamental Analysis FAQ
What is the fundamental rating for RX stock?
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA.
Can you provide the valuation status for BIOSYENT INC?
ChartMill assigns a valuation rating of 6 / 10 to BIOSYENT INC (RX.CA). This can be considered as Fairly Valued.
How profitable is BIOSYENT INC (RX.CA) stock?
BIOSYENT INC (RX.CA) has a profitability rating of 9 / 10.
What is the financial health of BIOSYENT INC (RX.CA) stock?
The financial health rating of BIOSYENT INC (RX.CA) is 9 / 10.
How sustainable is the dividend of BIOSYENT INC (RX.CA) stock?
The dividend rating of BIOSYENT INC (RX.CA) is 4 / 10 and the dividend payout ratio is 24.99%.